Desensitization of the human motilin receptor by motilides

Journal of Pharmacology and Experimental Therapeutics

Volumn 313, Issue 3, 2005, Pages 1397-1405

  Thielemans, Leen ^a   Depoortere, Inge ^a   Perret, Jason ^b   Robberecht, Patrick ^b   Liu, Yaoquan ^d   Thijs, Theo ^a   Carreras, Chris ^d   Burgeon, Emmanuel ^c   Peeters, Theo L ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c Euroscreen SA   (Belgium)

^d KOSAN BIOSCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4'' DEOXYERYTHROMYCIN A ENOL ETHER; 8,9 ANHYDRO N ETHYLNORERYTHROMYCIN A 6,9 HEMIACETAL; ALEMCINAL; CALCIUM ION; ENHANCED GREEN FLUORESCENT PROTEIN; ERYTHROMYCIN; ERYTHROMYCIN A ENOL ETHER; ERYTHROMYCIN B ENOL ETHER; KOS 1326; ME 36; ME 4; ME 67; MOTILIDE DERIVATIVE; MOTILIN; MOTILIN RECEPTOR; N ETHYL N METHYLERYTHROMYCIN A ENOL ETHER; PROKINETIC AGENT; RECEPTOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CALCULATION; CHO CELL; CONTROLLED STUDY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DUODENUM; FLUORESCENCE; HUMAN; INCUBATION TIME; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; RECEPTOR DOWN REGULATION; TACHYPHYLAXIS;

ANIMALS; CHO CELLS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROMYCIN; HUMANS; MUSCLE CONTRACTION; RADIOLIGAND ASSAY; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, NEUROPEPTIDE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 19444368316     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.081497     Document Type: Article

References (40)

1. Alewijnse AE, Smit MJ, Hoffmann M, Verzijl D, Timmerman H, and Leurs R (1998) Constitutive activity and structural instability of the wild-type human H2 receptor. J Neurochem 71:799-807.
2. Barak LS, Tiberi M, Freedman NJ, Kwatra MM, Lefkowitz RJ, and Caron MG (1994) A highly conserved tyrosine residue in G protein-coupled receptors is required for agonist-mediated beta 2-adrenergic receptor sequestration. J Biol Chem 269:2790-2795.
3. Benovic JL, Bouvier M, Caron MG, and Lefkowitz RJ (1988) Regulation of adenylyl cyclase-coupled beta-adrenergic receptors. Annu Reu Cell Biol 4:405-428.
4. Bologna SD, Hasler WL, and Owyang C (1993) Down-regulation of motilin receptors on rabbit colon myocytes by chronic oral erythromycin. J Pharmacol Exp Ther 226:852-856.
5. Borgland SL, Connor M, Osborne PB, Furness JB, and Christie MJ (2003) Opioid agonists have different efficacy profiles for G protein activation, rapid desensitization and endocytosis of mu-opioid receptors. J Biol Chem 278:18776-18784.
6. Bouaboula M, Dussossoy D, and Casellas P (1999) Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses. J Biol Chem 274:20397-20405.
7. Bruley des Varannes S, Parys V, Ropert A, Chayvialle JA, Roze C, and Galmiche JP (1995) Erythromycin enhances fasting and postprandial proximal gastric tone in humans. Gastroenterology 109:32-39.
8. Camilleri M (2002) Motilin agonists and dyspepsia: throwing out the baby with the bath water. Gut 51:612; author reply 612-613.
9. Ciruela F, Saura C, Canela EI, Mallol J, Lluis C, and Franco R (1997) Ligand-induced phosphorylation, clustering and desensitization of A1 adenosine receptors. Mol Pharmacol 52:788-797.
10. Depoortere I, Peeters TL, Matthijs G, Cachet T, Hoogmartens J, and Vantrappen G (1989) Structure-activity relation among macrolide antibiotics in inducing contractions and in displacing bund motilin in rabbit duodenum. J Gastrointest Motil 1:150-159.
11. Depoortere I, Peeters TL, and Vantrappen G (1991) Effect of erythromycin and of octreotide on motilin receptor density in the rabbit. Regul Pept 32:85-94.
12. Depoortere I, Verlinden M, Thijs T, Van Assche G, and Peeters TL (1999) The motilide ABT-229 selectively down regulates motilin receptors in different tissues. Evidence for motilin receptor subtypes. Gastroenterology 116:A1061.
13. Distrutti E, Azpiroz F, Soldevilla A, and Malagelada JR (1999) Gastric wall tension determines perception of gastric distention. Gastroenterology 116:1035-1042.
14. Ferguson SS (2001) Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53:1-24.
15. Filtz TM, Guan W, Artymyshyn RP, Facheco M, Ford C, and Molinoff PB (1994) Mechanisms of up-regulation of D2L dopamine receptors by agonists and antagonists in transfected HEK-293 cells. J Pharmacol Exp Ther 271:1574-1582.
16. Geurts M, Hermans E, and Maloteaux JM (1999) Enhanced striatal dopamine D(2) receptor-induced [35S]GTPgammaS binding after haloperidol treatment. Eur J Pharmacol 382:119-127.
17. Janssens J, Peeters T, Vantrappen G, Tack J, Urbain J, De Roo M, Muls E, and Bouillon R (1990) Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies [see comments]. N Engl J Med 322:1028-1031.
18. Keith DE, Murray SR, Zaki PA, Chu PC, Lissin DV, Rang L, Evans CJ, and von Zastrow M (1996) Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 271:19021-19024.
19. Kenakin T (2002a) Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 42:349-379.
20. Kenakin T (2002b) Efficacy at G-protein-coupled receptors. Nat Rev Drug Discov 1:103-110.
21. Lartey PA, Nellans HN, Faghih R, Petersen A, Edwards CM, Freiberg L, Quigley S, Marsh K, Klein LL, and Plattner JJ (1995) Synthesis of 4″-deoxy motilides: identification of a potent and orally active prokinetic drug candidate. J Med Chem 38:1793-1798.
22. Lewis MM, Watts VJ, Lawler CP, Nichols DE, and Mailman RB (1998) Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency. J Pharmacol Exp Ther 286:345-353.
23. Lowry DH, Rosenbrough MJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin fenol reagent. J Biol Chem 193:732-737.
24. Mahan LC, Koachman AM, and Insel PA (1985) Genetic analysis of beta-adrenergic receptor internalization and down-regulation. Proc Natl Acad Sci USA 82:129-133.
25. Omura S, Tsuzuki K, Sunazuka T, Marui S, Toyoda H, Inatomi N, and Itoh Z (1987) Macrolides with gastrointestinal motor stimulating activity. J Med Chem 30:1941-1943.
26. Peeters TL, Matthijs G, Depoortere I, Cachet T, Hoogmartens J, and Vantrappen G (1989) Erythromycin is a motilin receptor agonist. Am J Physiol 257:G470-G474.
27. Piessevaux H, Tack J, Wilmer A, Coulie B, Geubel A, and Janssens J (2001) Perception of changes in wall tension of the proximal stomach in humans. Gut 49:203-208.
28. Sternini C, Spann M, Anton B, Keith DE, Bunnett NW, von Zastrow M, Evans C, and Brecha NC (1996) Agonist-selective endocytosis of mu opioid receptor by neurons in vivo. Proc Natl Acad Sci USA 93:9241-9246.
29. Szekeres PG, Koenig JA, and Edwardson JM (1998) The relationship between agonist intrinsic activity and the rate of endocytosis of muscarinic receptors in a human neuroblastoma cell line. Mol Pharmacol 53:759-765.
30. Tack J and Peeters T (2001) What comes after macrolides and other motilin stimulants? Gut 49:317-318.
31. Talley NJ, Verlinden M, Geenen DJ, Hogan RB, Riff D, McCallum RW, and Mack RJ (2001) Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut 49:395-401
32. Talley NJ, Verlinden M, Snape W, Beker JA, Ducrotte P, Dettmer A, Brinkhoff H, Eaker E, Ohning G, Miner PB, et al. (2000) Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 14:1653-1661.
33. Thielemans L, Depoortere I, Vanden Broeck J, and Peeters TL (2002) The motilin pharmacophore in CHO cells expressing the human motilin receptor. Biochem Biophys Res Commun 293:1223-1227.
34. Thompson AK and Fisher SK (1990) Relationship between agonist-induced muscarinic receptor loss and desensitization of stimulated phosphoinositide turnover in two neuroblastomas: methodological considerations. J Pharmacol Exp Ther 252:744-752.
35. Toews ML and Perkins JP (1984) Agonist-induced changes in beta-adrenergic receptors on intact cells. J Biol Chem 259:2227-2235.
36. Tsao P, Cao T, and von Zastrow M (2001) Role of endocytosis in mediating down-regulation of G-protein-coupled receptors. Trends Pharmacol Sci 22:91-96.
37. Verhagen MA, Samsom M, Maes B, Geypens BJ, Ghoos YF, and Smout AJ (1997) Effects of a new motilide, ABT-229, on gastric emptying and postprandial antroduodenal motility in healthy volunteers. Aliment Pharmacol Ther 11:1077-1086.
38. Yu Y, Zhang L, Yin X, Sun H, Uhl GR, and Wang JB (1997) Mu opioid receptor phosphorylation, desensitization and ligand efficacy. J Biol Chem 272:28869-28874.
39. Zaki PA, Keith DE, Thomas JB, Carroll FI, and Evans CJ (2001) Agonist-, antagonist- and inverse agonist-regulated trafficking of the delta-opioid receptor correlates with, but does not require, G protein activation. J Pharmacol Exp Ther 298:1015-1020.
40. Zhang LJ, Lachowicz JE, and Sibley DR (1994) The D2S and D2L dopamine receptor isoforms are differentially regulated in Chinese hamster ovary cells. Mol Pharmacol 45:878-889.